Treovir’s Mission:
Developing Therapies for
Pediatric Brain Tumors
There are no approved therapies for Pediatric Brain tumors.
Current therapies are ineffective and have devastating side effects.
Treovir’s G207 Therapy demonstrated improved survival in a Phase 1 study without any serious side effects.
A TREOVIR
Nick Tasoglou came to UAB and Children’s of Alabama after being diagnosed with a brain tumor. 5 months after G207 treatment, scans showed holes forming in the tumor at the G207 injection sites. More than 7 years after a single G207 treatment, with no other therapies, Nick has shown a strong response.
Together We Can Achieve Our Common Vision:
The children come first, The families should have hope.
Treovir launched a Phase 2 clinical study for G207 in 2024 to treat pediatric patients with recurrent glioblastoma. Favorable data will be used to support market approval for G207 in Pediatric Brain Tumors, an incurable disease with no currently-approved therapies.
TREOVIR NEWS
